Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
67
KTTA Quote, Financials, Valuation and Earnings
Last price:
$1.16
Seasonality move
:
-5.84%
Day range:
$1.13 - $1.21
52-week range:
$0.28 - $3.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.71x
Volume:
168.3K
Avg. volume:
14.6M
1-year change:
-55.13%
Market cap:
$8.6M
Revenue:
--
EPS (TTM):
-$5.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
-- | -- | -- | -92.51% | $3.00 |
|
BEAT
HeartBeam, Inc.
|
-- | -- | -- | -- | $4.63 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
ENVB
Enveric Biosciences, Inc.
|
-- | -$0.55 | -- | -60% | $10.00 |
|
ONMD
OneMedNet Corp.
|
-- | -- | -- | -- | -- |
|
ZYXI
Zynex, Inc.
|
$24.5M | -$0.19 | -44.47% | -832.64% | $3.70 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
$1.16 | $3.00 | $8.6M | -- | $0.00 | 0% | -- |
|
BEAT
HeartBeam, Inc.
|
$2.73 | $4.63 | $94M | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$4.44 | $42.50 | $13.5M | -- | $0.00 | 0% | -- |
|
ENVB
Enveric Biosciences, Inc.
|
$4.67 | $10.00 | $2.4M | -- | $0.00 | 0% | 0.02x |
|
ONMD
OneMedNet Corp.
|
$1.29 | -- | $65.8M | -- | $0.00 | 0% | 99.76x |
|
ZYXI
Zynex, Inc.
|
$0.13 | $3.70 | $3.8M | 18.60x | $0.00 | 0% | 0.04x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
0.32% | -3.702 | 0.72% | 3.07x |
|
BEAT
HeartBeam, Inc.
|
-- | 1.449 | -- | 0.75x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
ENVB
Enveric Biosciences, Inc.
|
-- | -0.336 | -- | 4.15x |
|
ONMD
OneMedNet Corp.
|
-10.93% | 4.788 | 0.72% | 0.27x |
|
ZYXI
Zynex, Inc.
|
236.79% | 5.738 | 162.81% | 0.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
-$181.5K | -$3.1M | -91.9% | -92.48% | -- | -$2.9M |
|
BEAT
HeartBeam, Inc.
|
-$8K | -$5.3M | -555.14% | -555.14% | -- | -$3.2M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
ENVB
Enveric Biosciences, Inc.
|
-$40.4K | -$1.9M | -322.21% | -322.21% | -- | -$2.1M |
|
ONMD
OneMedNet Corp.
|
-$232K | -$2.2M | -- | -- | -1262.71% | -$1.6M |
|
ZYXI
Zynex, Inc.
|
$8.1M | -$13.2M | -88.52% | -709.17% | -98.97% | -$6.3M |
Pasithea Therapeutics Corp. vs. Competitors
-
Which has Higher Returns KTTA or BEAT?
HeartBeam, Inc. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of --. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat HeartBeam, Inc.'s return on equity of -555.14%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M BEATHeartBeam, Inc.-- -$0.15 $406K -
What do Analysts Say About KTTA or BEAT?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 158.62%. On the other hand HeartBeam, Inc. has an analysts' consensus of $4.63 which suggests that it could grow by 57.85%. Given that Pasithea Therapeutics Corp. has higher upside potential than HeartBeam, Inc., analysts believe Pasithea Therapeutics Corp. is more attractive than HeartBeam, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 BEATHeartBeam, Inc.2 1 0 -
Is KTTA or BEAT More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HeartBeam, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KTTA or BEAT?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HeartBeam, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. HeartBeam, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or BEAT?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than HeartBeam, Inc. quarterly revenues of --. Pasithea Therapeutics Corp.'s net income of -$3M is higher than HeartBeam, Inc.'s net income of -$5.3M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while HeartBeam, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus -- for HeartBeam, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M BEATHeartBeam, Inc.-- -- -- -$5.3M
-
Which has Higher Returns KTTA or CVM?
CEL-SCI Corp. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of --. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About KTTA or CVM?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 158.62%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 857.21%. Given that CEL-SCI Corp. has higher upside potential than Pasithea Therapeutics Corp., analysts believe CEL-SCI Corp. is more attractive than Pasithea Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 CVMCEL-SCI Corp.1 0 0 -
Is KTTA or CVM More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock KTTA or CVM?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or CVM?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Pasithea Therapeutics Corp.'s net income of -$3M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns KTTA or ENVB?
Enveric Biosciences, Inc. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of --. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat Enveric Biosciences, Inc.'s return on equity of -322.21%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M -
What do Analysts Say About KTTA or ENVB?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 158.62%. On the other hand Enveric Biosciences, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 2469.59%. Given that Enveric Biosciences, Inc. has higher upside potential than Pasithea Therapeutics Corp., analysts believe Enveric Biosciences, Inc. is more attractive than Pasithea Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 ENVBEnveric Biosciences, Inc.0 0 0 -
Is KTTA or ENVB More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Enveric Biosciences, Inc. has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.739%.
-
Which is a Better Dividend Stock KTTA or ENVB?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enveric Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. Enveric Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or ENVB?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than Enveric Biosciences, Inc. quarterly revenues of --. Pasithea Therapeutics Corp.'s net income of -$3M is lower than Enveric Biosciences, Inc.'s net income of -$1.9M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while Enveric Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus 0.02x for Enveric Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M
-
Which has Higher Returns KTTA or ONMD?
OneMedNet Corp. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of -418.64%. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat OneMedNet Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M ONMDOneMedNet Corp.-131.07% -$0.01 -$3.6M -
What do Analysts Say About KTTA or ONMD?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 158.62%. On the other hand OneMedNet Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pasithea Therapeutics Corp. has higher upside potential than OneMedNet Corp., analysts believe Pasithea Therapeutics Corp. is more attractive than OneMedNet Corp..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 ONMDOneMedNet Corp.0 0 0 -
Is KTTA or ONMD More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OneMedNet Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KTTA or ONMD?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OneMedNet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. OneMedNet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or ONMD?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than OneMedNet Corp. quarterly revenues of $177K. Pasithea Therapeutics Corp.'s net income of -$3M is lower than OneMedNet Corp.'s net income of -$741K. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while OneMedNet Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus 99.76x for OneMedNet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M ONMDOneMedNet Corp.99.76x -- $177K -$741K
-
Which has Higher Returns KTTA or ZYXI?
Zynex, Inc. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of -321.21%. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat Zynex, Inc.'s return on equity of -709.17%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M ZYXIZynex, Inc.60.47% -$1.42 $30.2M -
What do Analysts Say About KTTA or ZYXI?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 158.62%. On the other hand Zynex, Inc. has an analysts' consensus of $3.70 which suggests that it could grow by 2860%. Given that Zynex, Inc. has higher upside potential than Pasithea Therapeutics Corp., analysts believe Zynex, Inc. is more attractive than Pasithea Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 ZYXIZynex, Inc.1 0 0 -
Is KTTA or ZYXI More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zynex, Inc. has a beta of 0.987, suggesting its less volatile than the S&P 500 by 1.301%.
-
Which is a Better Dividend Stock KTTA or ZYXI?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zynex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. Zynex, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or ZYXI?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than Zynex, Inc. quarterly revenues of $13.4M. Pasithea Therapeutics Corp.'s net income of -$3M is higher than Zynex, Inc.'s net income of -$42.9M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while Zynex, Inc.'s PE ratio is 18.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus 0.04x for Zynex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M ZYXIZynex, Inc.0.04x 18.60x $13.4M -$42.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 4.16% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.99% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 3.04% over the past day.
